Qeb III kev kawm ntawm AbbVie lub qhov ncauj JAK inhibitor Rinvoq (upadacitinib) hauv kev kho mob me ntsis mus rau qhov tsis txaus AD yog qhov ua tiav!

AbbVie tsis ntev los no tshaj tawm tias Phase III AD Kev kawm tshawb xyuas qhov ncauj JAK1 inhibitor Rinvoq (upadacitinib) ua ke nrog tshuaj pleev corticosteroids (TCS) hauv kev kho mob ntawm atopic dermatitis (AD) tau mus txog qhov pib thiab tag nrho cov kev ua tiav.

Qhov no yog qhov thib peb piv rau Theem III kawm ntsuas Rinvoq hauv kev kho AD. TCS yog lub ntsiab kev kho mob rau AD. Cov ntaub ntawv zoo los ntawm AD Up muab ntau qhov kev pom rau Rinvoq ua ke nrog TCS. Cov ntaub ntawv qhia tau tias piv nrog cov tso placebo + TCS, Rinvoq + TCS tuaj yeem txhim kho tawv nqaij thiab khaus cov tsos mob. Tshwj xeeb, ntawm cov neeg mob kho nrog Rinvoq, qhov ntau dua ntawm cov neeg mob tuaj yeem tswj kev kho cov tsos mob ntawm daim tawv nqaij tsis tas yuav siv TCS.

Txoj kev kawm AD Up tau ua tiav rau cov hluas thiab cov laus uas muaj AD mus txog ntua rau AD loj. Nws ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm ob koob tshuaj Rinvoq (15mg thiab 30mg, ib hnub ib zaug) piv rau cov tshuaj placebo. Txhua pawg kho mob tau txais TCS tib lub sijhawm. Lub hom phiaj tseem ceeb kawg yog: ntawm 16 lub lim tiam ntawm kev kho mob, thaj tsam eczema thiab qhov mob hnyav tau nce los ntawm tsawg kawg 75% (EASI75), thiab kev soj ntsuam atopic dermatitis cov neeg soj ntsuam' s txhua qhov kev ntsuas (vIGA-AD) cov qhab nia ua tiav lossis yuav luag tiav kev tshem tawm cov tawv nqaij tawv nqaij (0/1).

Cov txiaj ntsig tau pom tias ntawm 16 lub lis piam ntawm kev kho mob, piv nrog cov placebo + pab pawg kho mob TCS, qhov feem ntau ntawm cov neeg mob hauv Rinvoq + TSC kho pab pawg ntawm txhua koob pom pom tias zoo dua ntawm daim tawv nqaij tshem tawm. Cov ntaub ntawv tshwj xeeb yog: (1) 65/77% ntawm cov neeg mob kho nrog 15 / 30mg koob tshuaj Rinvoq + TCS mus txog EASI75, thaum qhov feem pua ​​ntawm cov neeg mob kho nrog placebo + TCS yog 26% (p< 0.001);="" (2)="" 40/59%="" ntawm="" cov="" neeg="" mob="" kho="" nrog="" 15="" 30mg="" koob="" tshuaj="" rinvoq="" +="" tcs="" tiav="" viga-ad="" 0/1,="" thaum="" qhov="" feem="" pua="" ​​ntawm="" cov="" neeg="" mob="" kho="" nrog="" placebo="" +="" tcs="" yog="" 11%=""><>

Ib qho ntxiv, piv nrog cov neeg mob kho cov placebo + TCS, feem ntau ntawm cov neeg mob kho nrog Rinvoq + TCS muaj qhov txo qis mob ntawm qhov mob caj dab, txhais tau tias yog Qhov Kev Ntsuas Cov Ntshav Qeb Dua Tshaj Plaws (NRS) ≥ 4. Cov ntaub ntawv tshwj xeeb yog: hauv 16 lub lim tiam ntawm kev kho mob, 52/64% ntawm cov neeg mob uas tau txais 15 / 30mg koob tshuaj Rinvoq + TCS tau mus txog qhov kawg no, thaum cov feem ntawm placebo + TCS cov neeg mob tsuas yog 15% (p<>

Hauv kev soj ntsuam ua ntej ntxiv, kev kho mob nrog txhua koob tshuaj Rinvoq kuj ua rau cov hnub nruab nrab ntau dua hnub tsis muaj tshuaj pleev corticosteroids (hnub tsis pub TCS) piv rau cov placebo. Lub ntsiab lus ntawm TCS-dawb hnub yog kho cov lus teb ntawm EASI75 lossis siab dua tsis tas yuav siv TCS. Cov ntaub ntawv tshwj xeeb yog: hauv 16 lub lis piam ntawm kev kho mob, cov neeg mob uas tau txais 15 / 30mg koob tshuaj Rinvoq + TCS, cov hnub nyoog nruab nrab uas tsis muaj TCS thaum tswj EASI75 yog 34/47 hnub, thaum nruab nrab ntawm cov neeg mob tau txais placebo + TCS Nws yog 8 hnub (nom tswv p<>

Hauv txoj kev tshawb fawb no, cov txiaj ntsig kev nyab xeeb zoo ib yam nrog ob lub AD Ntu III kev tshawb fawb yav dhau los tshaj tawm. Nyob rau lub sijhawm 16-lub lim tiam txwv tsis pub tswj hwm, tsis muaj kev tiv thaiv kev nyab xeeb tshiab. Cov txiaj ntsig tag nrho ntawm cov kev tshawb fawb no yuav tshaj tawm tom kev sib tham txog kev kho mob yav tom ntej thiab luam tawm hauv cov ntawv txhua hnub.

Atopic dermatitis (AD) yog ib qho muaj tshwm sim, mob ntev, ib puag ncig, thiab mob ntawm daim tawv nqaij ua tshwm sim los ntawm kev rov ua dua ntawm khaus thiab khawb, ua rau mob tawv nqaij thiab tawg. Nws tau kwv yees tias ntau npaum li 25% ntawm cov neeg hluas thiab 10% ntawm cov neeg laus yuav muaj kev cuam tshuam los ntawm AD nyob rau qee lub sijhawm hauv lawv lub neej. 20% -46% ntawm cov neeg laus AD cov neeg mob yuav mob me ntsis mus rau mob hnyav. Cov tsos mob ntawm tus kab mob tuaj yeem ua rau lub cev tseem ceeb, lub hlwb thiab kev txom nyem ntawm cov neeg mob.

Lub tshuaj ua haujlwm ntawm Rinvoq yog upadacitinib, qhov ncauj tshuaj xaiv qhov ncauj thiab rov ua haujlwm JAK1 inhibitor nrhiav thiab tsim los ntawm AbbVie, uas tau tsim kho los kho ntau yam kab mob tiv thaiv kab mob. JAK1 yog kinase uas ua lub luag haujlwm tseem ceeb hauv pathophysiology ntawm ntau cov kab mob sib kis.

Thaum Lub Yim Hli 2019, Rinvoq tau txais lub ntiaj teb' s thawj pawg hauv Tebchaws Meskas rau kev kho mob me ntsis mus rau mob rheumatoid mob caj dab (RA) cov neeg laus uas tsis txaus los yog tsis mob siab rau methotrexate (MTX). Thaum Lub Kaum Ob Hlis 2019, Rinvoq tau pom zoo los ntawm European Union rau kev kho mob ntawm cov neeg mob uas muaj hnub nyoog mus rau mob hnyav RA uas tsis muaj peev xwm txaus los yog tsis teb rau ib lossis ntau hom kev kis mob antirheumatic (DMARD). Hauv RA, kev pom zoo koob tshuaj Rinvoq yog 15 mg.

Tam sim no, Rinvoq kho tus mob psoriatic mob caj dab (PsA), RA, axial spondyloarthritis (axSpA), Crohn's mob (CD), atopic dermatitis (AD), ulcerative colitis (UC), loj heev Phase III kev soj ntsuam ntawm Cellular Arteritis (GCA) tseem tab tom Cov.

Nyuam qhuav tsis ntev los no, AbbVie tshaj tawm tias nws tau xa daim ntawv thov tshiab rau Rinvoq (upadacitinib, 15 mg, ib hnub ib zaug) hauv Tebchaws Asmeskas thiab European Union rau kev kho mob ntawm cov neeg mob laus uas muaj PsA.

Kev lag luam muaj txiaj ntsig zoo txog Rinvoq' s lag luam pom tom ntej. Lub koom haum tshawb fawb kev lag luam tshuaj EvaluatePharma yav dhau los tshaj tawm tsab ntawv tshaj tawm hais tias Rinvoq' s muag thoob ntiaj teb xyoo 2024 yuav txog 2.57 txhiab daus las Asmeskas, ua lub ntiaj teb' s thib tsib zoo tshaj plaws tshuaj tiv thaiv kev mob rheumatic.